Junlin Ho Sells 9,580 Shares of Scholar Rock (NASDAQ:SRRK) Stock
Scholar Rock's General Counsel, Junlin Ho, sold 9,580 shares of the company's stock on February 17th for approximately $445,757, reducing their ownership by 3.81%. This follows a previous sale of 8,016 shares in January. The company (NASDAQ:SRRK) has a market capitalization of $4.87 billion, a consensus "Buy" rating from analysts with an average target price of $51.14, and high institutional ownership.
Rare-disease drug developer Scholar Rock to stream three investor talks
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company focused on rare neuromuscular diseases, announced that its management will participate in three upcoming investor conferences in March 2026. The company will hold fireside chats at the TD Cowen 46th Annual Health Care Conference, the Leerink Partners 2026 Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference. Live webcasts and replays of these events will be available on Scholar Rock's investor relations website.
Seven new Scholar Rock hires get 114,668 shares in inducement package
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards consisting of 114,668 shares to seven new employees. These awards include stock options for 64,226 shares and restricted stock units for 50,442 shares, granted under the company's 2022 Inducement Equity Plan. The grants aim to attract new talent and align their interests with the company's performance, as per Nasdaq Listing Rule 5635(c)(4).
Scholar Rock schedules March 3 call on 2025 financial results
Scholar Rock (NASDAQ: SRRK) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the market opens. The company will host a conference call and webcast with management at 8:00 a.m. ET to discuss the results. Interested participants can access the live audio webcast or register to join via telephone.
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Scholar Rock (NASDAQ: SRRK) announced it will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before market open. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Interested parties can access the webcast via Scholar Rock's investor relations website or register in advance for telephone participation.
Is Scholar Rock (SRRK) Pricing Reflect Its Strong Multi Year Share Performance Gains
Scholar Rock Holding (SRRK) closed at US$44.45, showing mixed returns over various periods, including a 308.9% gain over 3 years and an 18.4% decline over 5 years. A Discounted Cash Flow (DCF) analysis suggests the stock is 81.1% undervalued with an estimated intrinsic value of $235.71 per share, while its Price vs. Book ratio of 18.51x is significantly higher than the biotech industry average, indicating it might be overvalued by this metric. The article encourages investors to use "Narratives" on Simply Wall St's platform to form their own valuation based on personal assumptions.
Scholar Rock stock hits 52-week high at $48.46 By Investing.com
Scholar Rock Holding Corp's stock reached a 52-week high of $48.46, reflecting a 17.15% increase over the past year and a 28.19% return over six months. Despite analysts not anticipating profitability this year, the company's focus on innovative treatments and a strong financial position, with a $4.94 billion market capitalization and a current ratio of 6.3, contribute to growing investor confidence. Analyst ratings are largely positive, emphasizing the potential of its drug candidate apitegromab, even with a recent FDA warning letter to a manufacturing partner.
Scholar Rock stock hits 52-week high at $48.46
Scholar Rock Holding Corp's stock has surged to a 52-week high of $48.46, marking significant growth over the past year and six months. Despite analysts not anticipating profitability this year, the company's strong market capitalization and current ratio, coupled with positive analyst ratings and upcoming regulatory milestones for its drug apitegromab, indicate growing investor confidence in its future potential.
Scholar Rock stock hits 52-week high at $48.46 By Investing.com
Scholar Rock Holding Corp's stock has reached a 52-week high of $48.46, marking a significant increase of 17.15% over the past year and 28.19% over the last six months. This surge is attributed to investor confidence in the biotech firm's innovative treatments and strong financials, despite analysts not anticipating profitability this year. The company is advancing its pipeline, particularly with its drug candidate apitegromab, which has received positive attention and price target increases from several analysts.
SRRK: HC Wainwright Raises Price Target to $58, Maintains Buy Rating
HC Wainwright has reiterated its "Buy" rating for Scholar Rock Holding (SRRK) and increased its price target to $58 from $44, representing a 31.82% rise. This update follows several other analysts initiating coverage or raising price targets for SRRK recently, indicating a positive outlook for the company. Scholar Rock Holding, a biopharmaceutical company, focuses on developing medicines for serious diseases, with an average analyst target price of $49.36 and a consensus "Outperform" recommendation.
Insider Sell: Mo Qatanani Sells Shares of Scholar Rock Holding C
Mo Qatanani, Chief Scientific Officer at Scholar Rock Holding Corp (SRRK), sold 14,898 shares on January 22, 2026, reducing his holdings to 85,660 shares. This transaction is part of a larger trend at the company, which has seen 38 insider sells against only 2 insider buys over the past year. On the day of the sale, SRRK shares traded at $46.71, and investors are encouraged to consider various valuation metrics.
Marantz Jing L., chief medical officer at Scholar Rock, sells $257,881 in stock
Marantz Jing L., Chief Medical Officer at Scholar Rock (NASDAQ:SRRK), sold 5,798 shares of common stock worth $257,881 on January 16, 2026. This transaction was primarily to cover tax obligations related to restricted stock unit vesting. The company has also been the subject of several analyst reports, with some maintaining positive ratings despite recent regulatory challenges.
Ho Junlin, general counsel of Scholar Rock, sells $356k in SRRK
Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 8,016 shares of common stock for $356,533 on January 16, 2026, to cover tax withholding obligations from vested restricted stock units. This transaction occurred amidst several analyst updates, including UBS and Cantor Fitzgerald initiating or reiterating Buy/Overweight ratings for SRRK's lead candidate, apitegromab. Despite an FDA warning letter to a manufacturing partner and a past Complete Response Letter for apitegromab, the company is preparing for resubmission and scaling manufacturing.
Ho Junlin, general counsel of Scholar Rock, sells $356k in SRRK
Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 8,016 shares of common stock for $356,533 on January 16, 2026, to cover tax withholding obligations related to restricted stock unit vesting. Following the sale, Ho directly owns 214,553 shares. The company has also received recent attention from analysts, with UBS and Wolfe Research initiating coverage with "Buy" and "Outperform" ratings respectively, and BMO Capital raising its price target to $50.
Ho Junlin, general counsel of Scholar Rock, sells $356k in SRRK
Scholar Rock's General Counsel, Junlin Ho, sold 8,016 shares of common stock for $356,533 to cover tax withholding obligations related to restricted stock units. Following this transaction, Ho directly owns 214,553 shares. The company has recently received positive analyst ratings and is addressing manufacturing challenges to advance its lead candidate, apitegromab.
Ho Junlin, general counsel of Scholar Rock, sells $356k in SRRK
Scholar Rock's General Counsel, Junlin Ho, sold 8,016 shares of the company's common stock for approximately $356,533. This transaction was primarily to cover tax obligations related to the vesting of restricted stock units. Despite this insider sale, Scholar Rock has recently received positive analyst coverage and is working to bring its lead candidate, apitegromab, to market following some regulatory hurdles.
Caryn Parlavecchio, CHRO of Scholar Rock, sells $293k in shares By Investing.com
Caryn Parlavecchio, Chief Human Resources Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 6,600 shares of common stock totaling $293,552 on January 16, 2026. This transaction was primarily to cover tax obligations related to restricted stock units vesting and was not a discretionary trade. The article also highlights recent positive analyst ratings and strategic developments for Scholar Rock, despite some regulatory setbacks for its lead candidate, apitegromab.
Scholar Rock CSO Qatanani sells $373k in shares
Scholar Rock Holding's Chief Scientific Officer, Mo Qatanani, recently sold 8,406 shares of common stock for a total of $373,879. This sale was mandated by the company to cover tax obligations related to the vesting of restricted stock units. Despite this insider transaction, Scholar Rock has received positive analyst coverage and is moving forward with its lead candidate, apitegromab, for rare-disease treatment.
Caryn Parlavecchio, CHRO of Scholar Rock, sells $293k in shares
Caryn Parlavecchio, Chief Human Resources Officer of Scholar Rock Holding Corp, sold 6,600 shares totaling $293,552 on January 16, 2026. This sale was to cover tax obligations from vested restricted stock units and was not a discretionary trade. The company has recently garnered increased analyst attention, with several firms initiating or reiterating "Buy" or "Outperform" ratings, primarily due to its lead candidate, apitegromab.
Marantz Jing L., chief medical officer at Scholar Rock, sells $257,881 in stock
Marantz Jing L., Chief Medical Officer at Scholar Rock (NASDAQ: SRRK), sold 5,798 shares of company stock for $257,881 to cover tax obligations from vested restricted stock units. Following this transaction, Marantz still holds 95,687 shares. The article also mentions recent analyst coverage and company updates regarding Scholar Rock's lead candidate, apitegromab, including a mix of positive ratings and regulatory challenges.
Ho Junlin, general counsel of Scholar Rock, sells $356k in SRRK
Junlin Ho, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 8,016 shares of common stock for $356,533 to cover tax obligations related to restricted stock unit vesting. Following the sale, Ho directly owns 214,553 shares, comprising common stock and RSUs. This transaction comes amidst various analyst updates and company developments, including new coverage with "Buy" and "Outperform" ratings from UBS and Wolfe Research, respectively, and a raised price target from BMO Capital.
Scholar Rock Reports New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)
Scholar Rock announced inducement equity awards for two new employees, comprising stock options for 20,400 shares and restricted stock units for 14,800 shares. These grants, made under Nasdaq Listing Rule 5635(4), are intended to attract new talent and are subject to specific vesting schedules tied to the employees' continued service. The stock options have an exercise price of $43.56, matching the closing price on January 12, 2026.
Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 13,112 Shares of Stock
Scholar Rock (NASDAQ:SRRK) insider Mo Qatanani recently sold 13,112 shares of the company's stock for approximately $592,662, reducing his stake by over 10%. This sale, along with other executive sales in mid-January, coincided with a 3.4% drop in the stock price, adding to supply pressure. Despite recent EPS misses, analysts maintain a "Buy" rating with an average target price of $50.14, indicating a generally positive outlook.
Two new Scholar Rock hires receive 35,200-share equity grant package
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards totaling 35,200 shares of common stock to two new employees. These grants include stock options for 20,400 shares and restricted stock units for 14,800 shares, issued under the company's 2022 Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are designed to attract and retain talent, with vesting schedules tied to continued employment.
Insider Selling: Scholar Rock (NASDAQ:SRRK) COO Sells 16,746 Shares of Stock
Scholar Rock Holding Corporation COO Keith Woods sold 16,746 shares of his company's stock on January 13th, 2026, for over $715,000, reducing his position by 2.79%. The transaction was disclosed in an SEC filing. The biotech company's stock was trading up 2.1% at $46.53, and analysts maintain a consensus "Buy" rating with an average price target of $50.14.
Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 20,438 Shares of Stock
Scholar Rock (NASDAQ:SRRK) insider Akshay Vaishnaw sold 20,438 shares of the company's stock on January 13th at an average price of $42.70, totaling over $872,000. This transaction reduced his stake by 3.32% to 595,767 shares. The stock traded up 2.1% to $46.53 on Thursday, with analysts holding a consensus "Buy" rating and a $50.14 price target despite the company missing quarterly EPS estimates.
Scholar Rock (NASDAQ:SRRK) CEO David Hallal Sells 57,450 Shares
Scholar Rock CEO David Hallal sold 57,450 shares on January 13th for approximately $2.45 million, reducing his stake by 3.59%. The company's stock traded at $46.53 mid-day, with a market cap of $4.75 billion and a negative P/E of -14.77. Analysts largely hold a "Buy" rating for SRRK, with an average target price of $50.14.
Scholar Rock (SRRK) COO Woods sells $715k in stock
Scholar Rock Holding Corp's COO, Keith Woods, sold 16,746 shares totaling $715,054 to cover tax obligations from vested restricted stock units. Despite the sale, his direct ownership remains substantial, and the company maintains a strong liquidity position, although InvestingPro suggests it may be overvalued. Recent analyst updates and company developments, including a mixed outlook on its lead candidate apitegromab due to regulatory challenges, continue to influence investor perception.
Hallal, CEO of Scholar Rock, sells $2.45 million in SRRK stock
David Hallal, CEO of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 57,450 shares totaling $2.45 million to cover tax obligations related to vested restricted stock units. Despite the sale, Hallal retains substantial direct and indirect ownership in the company, which has a market capitalization of $4.72 billion and a strong liquidity position. The company's lead candidate, apitegromab, is garnering positive analyst ratings and moving towards a potential U.S. launch in 2026 despite some regulatory hurdles.
Scholar Rock (SRRK) COO Woods sells $715k in stock By Investing.com
Scholar Rock Holding Corp's COO, Keith Woods, sold 16,746 shares amounting to over $715,000 to cover tax obligations from vested restricted stock units. This occurred while the stock was trading near its 52-week high, and the company maintains a strong financial position. Analyst firms like UBS, Cantor Fitzgerald, and Wolfe Research have provided positive ratings and price targets for Scholar Rock, focusing on its lead candidate apitegromab, despite recent regulatory challenges.
Scholar Rock CFO Sinha sells $715k in shares
Scholar Rock Holding Corp CFO Vikas Sinha sold 16,755 shares of common stock for over $715,000 on January 13, 2026, primarily to cover tax obligations related to vested restricted stock units. Despite this sale, Sinha still owns a significant number of shares, RSUs, and PSUs. The company has recently received positive analyst coverage and is navigating regulatory challenges for its lead drug candidate, apitegromab.
Scholar Rock Executives Sell Shares to Cover Tax Obligations
Several executives at Scholar Rock Holding Corp (SRRK) recently sold shares of the company's stock to cover tax obligations stemming from the vesting of restricted stock units. CEO David Hallal, President of R&D Vaishnaw Akshay, COO Keith Woods, and CFO Vikas Sinha each sold a significant number of shares at $42.7 per share, impacting their direct and indirect holdings. These transactions were primarily for tax withholding purposes.
Hallal, CEO of Scholar Rock, sells $2.45 million in SRRK stock
David Hallal, CEO of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 57,450 shares for $2.45 million to cover tax obligations related to vesting restricted stock units. Despite the sale, Hallal retains significant holdings in the company. Scholar Rock, with a $4.72 billion market cap, is not yet profitable but maintains strong liquidity and has received positive analyst coverage for its lead candidate, apitegromab.
Vaishnaw, Scholar Rock president, sells $872k in shares
Akshay Vaishnaw, President of Research and Development at Scholar Rock Holding Corp (NASDAQ:SRRK), sold 20,438 shares for $872,702 to cover tax withholding obligations. Following the sale, SRRK shares have increased by 9%, and Vaishnaw still holds a significant number of shares and units in the company. Scholar Rock is trading above its Fair Value, holding a Strong Buy consensus, and is navigating regulatory challenges while preparing for a potential U.S. launch of its lead candidate, apitegromab, in 2026.
SRRK: Analyst Maintains Rating but Lowers Price Target to $44
HC Wainwright & Co. has maintained its "Buy" rating for Scholar Rock Holding (SRRK) but has lowered its price target from $50.00 to $44.00, representing a 12% decrease. This adjustment was cited by analyst Andres Y. Maldonado due to a revised valuation. Despite the lowered target, the average target price from 8 analysts is $50.63, implying a 57.49% upside from the current price, and the average brokerage recommendation indicates an "Outperform" status.
New muscle-targeting SMA drug could reach children and adults in 2026
Scholar Rock is focused on advancing its muscle-targeted drug, apitegromab, with anticipated FDA approval and commercial launch in the U.S. and Europe in 2026 for the treatment of spinal muscular atrophy (SMA) in children and adults. The company is actively working on regulatory resubmissions, preparing commercial capacity, and expanding its pipeline to include new formulations and treatments for other neuromuscular diseases like facioscapulohumeral muscular dystrophy (FSHD). Scholar Rock also reported approximately $365 million in cash, expected to fund operations into 2027.
SRRK Receives New 'Buy' Rating from Citigroup with $55 Price Tar
Citigroup has initiated coverage on Scholar Rock Holding (SRRK) with a 'Buy' rating and a $55 price target, reflecting continued analyst confidence in the company. This follows several other positive ratings and price target increases from UBS, Barclays, JP Morgan, and Wolfe Research. Analysts forecast an average target price of $48.85 for SRRK, implying a 17.22% upside from its current price, and maintain an "Outperform" status based on brokerage firm recommendations.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of "Buy" by Brokerages
Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus "Buy" recommendation from sixteen brokerages, with an average 12-month price target of $48.92. Despite notable insider selling and missing Q3 2025 earnings estimates, analysts maintain a positive outlook, with several reiterating "Overweight" or "Outperform" ratings and price target increases. The company, a clinical-stage biotechnology firm, focuses on developing protein therapeutics for growth factor-involved diseases, with its lead program SRK-015 in evaluation for spinal muscular atrophy.
SRRK: UBS Initiates Coverage with a 'Buy' Rating and $60 Price Target | SRRK Stock News
UBS has initiated coverage on Scholar Rock Holding (SRRK) with a 'Buy' rating and set a price target of $60 USD, indicating a positive outlook for the biopharmaceutical company. This new coverage adds to a series of recent analyst activities, where other firms like Barclays, JP Morgan, and Wolfe Research have also maintained or initiated 'Overweight'/'Outperform' ratings with various price target adjustments. Scholar Rock Holding, which focuses on developing innovative medicines for serious diseases, now has an average target price of $47.92 from 12 analysts, suggesting a potential upside of 9.45% from its current price.
UBS initiates Scholar Rock stock with Buy rating, sets $60 price target
UBS has initiated coverage on Scholar Rock (NASDAQ:SRRK) with a Buy rating and a $60 price target, highlighting the potential of its lead candidate apitegromab for spinal muscular atrophy (SMA). Despite recent regulatory and earnings challenges, UBS views the stock as undervalued, citing apitegromab's blockbuster potential and strong long-term growth opportunities in the over $5 billion SMA market. Other analysts like Cantor Fitzgerald, Wolfe Research, and BMO Capital have also expressed confidence in the company's prospects.
Biotech focused on rare muscle diseases joins J.P. Morgan health conf
Scholar Rock (SRRK), a biopharmaceutical company specializing in treatments for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will present on January 12 at 7:30 a.m. PST (10:30 a.m. EST), with a live webcast available for investors. The company focuses on myostatin biology to develop therapies for musculoskeletal health.
Scholar Rock's chief commercial officer sells $171,927 in common stock
Scholar Rock's Chief Commercial Officer, Paul Marcotte, recently sold 10,000 shares of the company's common stock for a total of $171,927. This transaction occurred at an average price of $17.19 per share. Following the sale, Marcotte still directly owns 101,311 shares of Scholar Rock stock.
Scholar Rock Holding Corporation $SRRK Shares Acquired by Moody Aldrich Partners LLC
Moody Aldrich Partners LLC increased its stake in Scholar Rock Holding Corporation by 53.5% to 101,742 shares, now valued at approximately $3.79 million. This acquisition is part of broader institutional interest, with hedge funds and other institutional investors owning 91.08% of the company's stock. Despite a recent earnings per share miss, analysts maintain a "Buy" rating with an average target price of $48.92.
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears
Scholar Rock (SRRK) shares dropped 3.2% today, reversing earlier gains, as investors remain focused on the timing of a year-end manufacturing reinspection crucial for its lead drug candidate, apitegromab. The FDA had previously issued an "official action indicated" status for a key manufacturing site, leading to a resubmission delay. The stock's near-term valuation hinges on regulatory timing, with a BLA resubmission anticipated in 2026 and a new fill-finish facility expected to commercial capacity by early 2026.
Scholar Rock Holding Corporation $SRRK Shares Bought by Voya Investment Management LLC
Voya Investment Management LLC increased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 18.1% during the third quarter, bringing its total to 443,155 shares valued at $16.5 million. Institutional investors now collectively own 91.08% of the company, while insider activity showed mixed signals with a significant sale by Mo Qatanani and a purchase by director Srinivas Akkaraju. The company's stock, with a market cap of $4.61 billion, has been given an average "Buy" rating by analysts, with a consensus target price of $48.92, despite missing its recent EPS estimate.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 13, 2025
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards for two newly hired employees, consisting of stock options for 4,457 shares and restricted stock units for 3,343 shares of its common stock. These grants are part of the Company’s 2022 Inducement Equity Plan, specifically under Nasdaq Listing Rule 5635(c)(4), designed to attract new talent. The awards vest over several years, subject to continued employment, with stock options having an exercise price matching the closing price on December 8, 2025.
Scholar Rock (NASDAQ: SRRK) grants 7,800-share inducement awards at $45.25 exercise price
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards covering 7,800 shares of its common stock to two new employees. These awards include stock options for 4,457 shares and restricted stock units for 3,343 shares, granted under the company's 2022 Inducement Equity Plan. The exercise price for the stock options is $45.25, reflecting the closing price on December 8, 2025.
Scholar Rock stock rating reiterated as Overweight by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating on Scholar Rock (NASDAQ:SRRK), maintaining a positive outlook due to high confidence in the approval prospects for its lead drug candidate, apitegromab. The stock is currently trading at $45.05 with a market capitalization of $4.6 billion, just below its 52-week high. Analyst Eric Schmidt expects apitegromab's approval to make Scholar Rock a top performer in 2026, aiming for a multi-billion dollar franchise.
Scholar Rock stock reaches 52-week high at 47.01 USD
Scholar Rock Holding Corp's stock has hit a 52-week high of $47.01 USD, marking a significant milestone for the biotechnology company with a 36.47% surge in the last six months. Despite positive investor sentiment and a Strong Buy consensus from analysts, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company recently reported mixed Q3 2025 earnings and is planning to resubmit its biologics license application for apitegromab in 2026, with several firms maintaining positive ratings despite an FDA setback.
Scholar Rock (SRRK) Valuation Revisited After FDA Warning Letter to Key Manufacturing Partner
Scholar Rock (SRRK) is under scrutiny after its manufacturing partner, a former Catalent site now owned by Novo Nordisk, received an FDA warning letter, raising concerns about the launch timing of its drug, apitegromab. Despite this, the stock has shown momentum, with a significant 1-month share price return. While its price-to-book ratio appears high compared to the broader biotech sector, the company's valuation based on the Simply Wall St DCF model suggests it is deeply undervalued by the market.
